Sign in

CIK 0001395937 · Large accelerated filer

Syndax Pharmaceuticals Inc

Sign in to watch
Ticker
SNDX
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
operating
EIN
320162505
Phone
781-419-1400
Business address
730 THIRD AVENUE, 9TH FLOOR, NEW YORK, NY, 10017
  1. 4 Open-market sale Chief Executive Officer sold 16,231 shares at $25.29 ($410,508)
  2. 4 Open-market sale Chief Executive Officer sold 33,769 shares at an average $25.02 ($844,890)
  3. 4 Open-market sale Director sold 4,101 shares at an average $25.06 ($102,777)
  4. 8-K Event Agreement ended · Regulation FD disclosure
  5. 4 Open-market sale President, Head of R&D sold 173,988 shares at an average $23.11 ($4,020,056)
  6. 4 Open-market sale President, Head of R&D sold 279,420 shares at an average $23.64 ($6,604,327)
  7. 4 Open-market sale Director sold 78,815 shares at an average $24.08 ($1,897,988)
  8. 4 Open-market sale Chief Scientific Officer sold 25,000 shares at $25.04 ($625,893)
  9. 4 Open-market sale Director sold 24,000 shares at $23.02 ($552,382)
  10. 10-Q Report Quarterly Report
  11. 8-K Event Results of operations
  12. 4 Open-market sale Chief Executive Officer sold 31,602 shares at $21.06 ($665,393)
  13. 4 Open-market sale Chief Executive Officer sold 15,109 shares at an average $21.07 ($318,407)
  14. 4 Open-market sale President, Head of R&D sold 62,292 shares at $19.00 ($1,183,430)
  15. 4 Grant or award Chief Financial Officer acquired 3,205 shares (grant or award)
  16. 3 Insider Initial Statement of Ownership
  17. 8-K Event Executive or director change
  18. 8-K Event Shareholder vote results
  19. 8-K Event Results of operations
  20. 10-Q Report Quarterly Report

Page 13 of 33 · 660 filings